Type 1 Diabetes
CVrg’s coverage of Type 1 Diabetes includes comprehensive coverage of basal and prandial insulins, biosimilar insulins, immunomodulators, cell therapies, GLP-1 agonists, SGLT-2 and dual SGLT-1/2 inhibitors, and emerging novel therapies.
Senior Director, CV Risk Factors and Metabolic Diseases
Liz received her doctorate from London University and brings more than 20 years of Pharmaceutical Industry experience, primarily supporting Competitor Intelligence in cardiovascular therapeutic areas. Liz has directed CVrg’s metabolic research since 2009 and serves clients through her deep knowledge of the disease areas, strong business acumen, command of analytical methods, excellent communication skills, and widespread credibility in the industry.
Nina Brandt, Ph.D.
Therapy Area Manager, Metabolic Diseases
Dr. Brandt received her Ph.D. in Exercise Physiology from University of Copenhagen, where her research focused on the interplay between lipids and insulin signaling in pre-clinical and clinical models of obesity, followed by postdoctoral training at UCLA specializing in metabolic disease in specific patient populations.
|CVrg Market Strategies™||
Type 1 Diabetes, 2019–2028 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market landscapes.
KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in T1D from CVrg Sentinel, Conference, Insights and Advisory research are also included.
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of T1D assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ADA and EASD. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why.
|*CVrg KOL Insights™||
CVrg experts conduct primary research with KOLs in T1D, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today. *Additional fees may apply.
answers & new content
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in T1D drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.